Elicio hosts KOL event on ELI-002 7P for metastatic mKRAS PDAC; no new data disclosed

Elicio Therapeutics, Inc.

Virtual KOL event on June 24, 2026 featured Dr. Zev Wainberg (UCLA) and Dr. Peter Hosein (U. Miami).
Event discussed path forward for ELI-002 7P in metastatic mutant KRAS-driven pancreatic ductal adenocarcinoma.
No specific clinical data, enrollment updates, or financial guidance were included in the filed material.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.